The Prostate Cancer Program (05) has 3 central themes: 1) mechanisms of castration resistance;2) molecular targeting;and 3) translational studies, both clinical and preclinical. The major program emphasis is on the study of the mechanisms of aberrant androgen receptor (AR) activation in the development of castration resistant prostate cancer (CRPC). Studies to understand the function and regulation of AR divide into 3 areas: a) regulation of intracrine androgens, b) aberrant AR activation, and c) the role of co-regulators. Molecular targeting of CRPC focuses on the role of neuropeptides, kinase inhibitors, and the role of autophagy. In translational studies, eight different targets are under investigation, four of which have progressed to investigator-initiated clinical trials. Our long-term goal is to develop mechanism-based treatments for CRPC and castration-adjunctive therapy that may lead to a more effective intervention than castration alone. The program has 17 members from 8 different departments and divisions. It has 8 NCl-funded projects for $1.1 million ADC (total peer-reviewed funding, $3.1 million ADC). The group has 320 publications;54% are inter-programmatic and 26% are intra-programmatic

Public Health Relevance

Patients die of prostate cancer because the tumors learn to bypass the effects of therapeutic strategies aimed at reducing the supply of androgens to the cancer. This is called castration resistant prostate cancer. The program is aimed at understanding why this occurs, attempting to prevent its occurrence, and developing therapies to treat it once it has occurred.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-12
Application #
8743643
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
12
Fiscal Year
2014
Total Cost
$22,223
Indirect Cost
$7,745
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Seo, Jai Woong; Tavaré, Richard; Mahakian, Lisa M et al. (2018) CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clin Cancer Res 24:4976-4987
Yuan, Ye; He, Yixuan; Bo, Ruonan et al. (2018) A facile approach to fabricate self-assembled magnetic nanotheranostics for drug delivery and imaging. Nanoscale 10:21634-21639
Knight, Jennifer F; Sung, Vanessa Y C; Kuzmin, Elena et al. (2018) KIBRA (WWC1) Is a Metastasis Suppressor Gene Affected by Chromosome 5q Loss in Triple-Negative Breast Cancer. Cell Rep 22:3191-3205
Xue, Xiangdong; Huang, Yee; Bo, Ruonan et al. (2018) Trojan Horse nanotheranostics with dual transformability and multifunctionality for highly effective cancer treatment. Nat Commun 9:3653
Dou, John; Schmidt, Rebecca J; Benke, Kelly S et al. (2018) Cord blood buffy coat DNA methylation is comparable to whole cord blood methylation. Epigenetics 13:108-116
Couto, K M; Moore, P F; Zwingenberger, A L et al. (2018) Clinical characteristics and outcome in dogs with small cell T-cell intestinal lymphoma. Vet Comp Oncol 16:337-343
Xue, Xiangdong; Huang, Yee; Wang, Xinshuai et al. (2018) Self-indicating, fully active pharmaceutical ingredients nanoparticles (FAPIN) for multimodal imaging guided trimodality cancer therapy. Biomaterials 161:203-215
Ho, Pui Yan; Duan, Zhijian; Batra, Neelu et al. (2018) Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy. J Pharmacol Exp Ther 365:494-506
Zuo, Yang; Qi, Jinyi; Wang, Guobao (2018) Relative Patlak plot for dynamic PET parametric imaging without the need for early-time input function. Phys Med Biol 63:165004
McGee, Heather M; Daly, Megan E; Azghadi, Sohelia et al. (2018) Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. Int J Radiat Oncol Biol Phys 101:1259-1270

Showing the most recent 10 out of 836 publications